default author photo

Ugo De Giorgi

IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST) - Clinical and Experimental Oncology Unit

SCHOLARLY PAPERS

3

DOWNLOADS

282

TOTAL CITATIONS

1

Scholarly Papers (3)

1.

MITO END-3: A Randomized Phase II Trial of Avelumab Plus Carboplatin and Paclitaxel Compared to Carboplatin and Paclitaxel in Advanced or Recurrent Endometrial Cancer

Number of pages: 32 Posted: 27 Dec 2022
Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale - Uro-Gynecological Medical Oncology, Catholic University of the Sacred Heart, Rome - Gynecologic Oncology Unit, Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale - Clinical Trial Unit, Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale - Clinical Trial Unit, Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale - Uro-Gynecological Medical Oncology, Centro di Riferimento Oncologico - Medical Oncology and Oncological Prevention Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST) - Clinical and Experimental Oncology Unit, Azienda Sanitaria Universitaria Friuli Centrale - Oncology Department, “Senatore Antonio Perrino” Hospita - Medical Oncology Unit, Baylor University - Lester and Sue Smith Breast Center, Oncology Unit, “S. Vincenzo” Hospital, S. Maria delle Croci Hospital - Oncology Unit, Infermi Hospital - Medical Oncology Unit, Mater Salutis Hospital AULSS9, “Scaligera” - Medical Oncology Unit, Medical Oncology Unit “Santo Stefano” Hospital, Niguarda Ca' Granda Hospital - Oncology Unit, IRCCS Ospedale Policlinico San Martino - U.O. Clinica di Oncologia Medica, Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale - Uro-Gynecological Medical Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS - Department of Woman, Child and Public Health, Centro di Riferimento Oncologico - Medical Oncology and Oncological Prevention Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST) - Clinical and Experimental Oncology Unit, Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale - Uro-Gynecological Medical Oncology, Catholic University of the Sacred Heart, Rome - Gynecologic Oncology Unit, Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale - Clinical Trial Unit, Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale - Microenvironment Molecular Targets Unit, Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale - Microenvironment Molecular Targets Unit, Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale - Microenvironment Molecular Targets Unit, Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale - Pathological Anatomy and Cytopathology Unit, University of Campania “Luigi Vanvitelli” - Medical Statistics and Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale - Clinical Trial Unit
Downloads 126 (572,948)

Abstract:

Loading...

Endometrial Cancer, First-line treatment, Chemotherapy, Avelumab

2.

Contralateral Prophylactic Mastectomy and Oophorectomy Increase the Survival in Brca-Related Breast Cancer: The Italian Mutina Study

Number of pages: 32 Posted: 08 May 2024
Università di Modena e Reggio Emilia, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, University Hospital of Parma, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST) - Clinical and Experimental Oncology Unit, affiliation not provided to SSRN, affiliation not provided to SSRN, Regione Emilia-Romagna - IRCCS Azienda Ospedaliero-Universitaria di Bologna, affiliation not provided to SSRN and affiliation not provided to SSRN
Downloads 78 (816,709)

Abstract:

Loading...

BRCA1, BRCA2, Contralateral Prophylactic Mastectomy, overall survival

3.

Impact of Teratoma on Survival Probabilities of Patients with Metastatic Non-Seminomatous Germ Cell Cancer

Number of pages: 54 Posted: 27 Feb 2024
European Organisation for Research and Treatment of Cancer (EORTC), European Organisation for Research and Treatment of Cancer (EORTC), University of Copenhagen - Department of Oncology, Erasmus University Medical Center - Department of Medical Oncology, Indiana University - Melvin and Bren Simon Comprehensive Cancer Center, N.N. Blokhin Russian Cancer Research Center, Université Paris XI Sud - Gustave Roussy Cancer Campus, Lund University - Skåne University Hospital, University Medical Centre Groningen, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST) - Clinical and Experimental Oncology Unit, University College London - MRC Clinical Trials Unit, University of Toronto - Princess Margaret Cancer Centre, St. Olavs University Hospital, Royal Marsden NHS Foundation Trust - Department of Oncology, Università Vita-Salute San Raffaele - IRCCS San Raffaele Scientific Institute, University of Adelaide, University of Barcelona - Institut Català d'Oncologia - Hospitalet, IDIBELL, University of Calgary - Tom Baker Cancer Center, University of Zurich - Department of Medical Oncology and Hematology, Medical Faculty Comenius University, Western University, Canada, The University of Sydney - NHMRC Clinical Trials Centre, Memorial Sloan Kettering Cancer Center, Medical University of Graz - Division of Oncology, Ludwig Maximilian University of Munich (LMU) - Department of Hematology and Oncology, University of Hamburg - Department of Hematology, Oncology and Bone Marrow Transplantation with Section of Pneumology, University of Oslo - Department of Oncology, University of Zurich, Government of the United Kingdom - St Bartholomew's Hospital, University of Pennsylvania, San Camillo Forlanini Hospital, University of Cologne - University Hospital of Cologne, European Organisation for Research and Treatment of Cancer (EORTC), Oncology Institute of Southern Switzerland and University of Bern
Downloads 78 (816,709)
Citation 1

Abstract:

Loading...

germ-cell tumours, teratoma, non-seminoma, Prognosis, IGCCCG